| 前收盘价格 | 9.14 |
| 收盘价格 | 9.04 |
| 成交量 | 1,481,664 |
| 平均成交量 (3个月) | 2,303,509 |
| 市值 | 628,574,976 |
| 价格/销量 (P/S) | 2.39 |
| 股市价格/股市净资产 (P/B) | 1.07 |
| 52周波幅 | |
| 利润日期 | 1 May 2025 - 5 May 2025 |
| 营业毛利率 | -75.51% |
| 营业利益率 (TTM) | -98.31% |
| 稀释每股收益 (EPS TTM) | -2.77 |
| 季度收入增长率 (YOY) | 196.00% |
| 总债务/股东权益 (D/E MRQ) | 1.73% |
| 流动比率 (MRQ) | 4.64 |
| 营业现金流 (OCF TTM) | -259.30 M |
| 杠杆自由现金流 (LFCF TTM) | -99.28 M |
| 资产报酬率 (ROA TTM) | -13.05% |
| 股东权益报酬率 (ROE TTM) | -32.56% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Arvinas, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
0.3
| 分析师共识 | 1.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.25 |
|
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 7.62% |
| 机构持股比例 | 110.17% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| New Leaf Venture Partners, L.L.C. | 31 Dec 2024 | 1,585,721 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 81.00 (HC Wainwright & Co., 795.03%) | 购买 |
| 中 | 26.00 (187.29%) | |
| 低 | 12.00 (Goldman Sachs, 32.60%) | 保留 |
| 12.00 (Morgan Stanley, 32.60%) | 保留 | |
| 12.00 (Wedbush, 32.60%) | 保留 | |
| 平均值 | 30.08 (232.38%) | |
| 总计 | 9 购买, 4 保留 | |
| 平均价格@调整类型 | 11.25 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Goldman Sachs | 17 Apr 2025 | 12.00 (32.60%) | 保留 | 8.60 |
| Truist Securities | 09 Apr 2025 | 21.00 (132.04%) | 购买 | 6.73 |
| HC Wainwright & Co. | 07 Apr 2025 | 81.00 (795.03%) | 购买 | 6.37 |
| 14 Mar 2025 | 81.00 (795.03%) | 购买 | 8.43 | |
| Guggenheim | 13 Mar 2025 | 32.00 (253.59%) | 购买 | 8.55 |
| 12 Feb 2025 | 57.00 (529.83%) | 购买 | 17.95 | |
| Morgan Stanley | 13 Mar 2025 | 12.00 (32.60%) | 保留 | 8.55 |
| B of A Securities | 12 Mar 2025 | 28.00 (209.39%) | 购买 | 9.03 |
| BMO Capital | 12 Mar 2025 | 20.00 (120.99%) | 购买 | 9.03 |
| 12 Feb 2025 | 82.00 (806.08%) | 购买 | 17.95 | |
| Wedbush | 12 Mar 2025 | 12.00 (32.60%) | 保留 | 9.03 |
| Wells Fargo | 12 Mar 2025 | 26.00 (187.29%) | 购买 | 9.03 |
| Citigroup | 07 Mar 2025 | 19.00 (109.94%) | 保留 | 18.28 |
| Oppenheimer | 12 Feb 2025 | 45.00 (397.24%) | 购买 | 17.95 |
| Stifel | 12 Feb 2025 | 51.00 (463.54%) | 购买 | 17.95 |
| Barclays | 03 Feb 2025 | 32.00 (253.59%) | 购买 | 17.10 |
| 显示更多 | ||||
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合